Invasive community-associated MRSA infections: epidemiology and antimicrobial management (Q37800939)

23 August 2017

title

Invasive community-associated MRSA infections: epidemiology and antimicrobial management (English)

1 reference

23 August 2017

1 reference

Solen Pichereau

1

1 reference

23 August 2017

Warren E Rose

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

19 October 2010

1 reference

Expert Opinion on Pharmacotherapy

23 August 2017

published in

1 reference

23 August 2017

volume

11

1 reference

23 August 2017

issue

18

1 reference

23 August 2017

page(s)

3009-3025

1 reference

Community-associated methicillin-resistant Staphylococcus aureus: new bug, old drugs

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Clinical decisions. Management of skin and soft-tissue infection--polling results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Preferred treatment and prevention strategies for recurrent community-associated methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: a survey of adult and pediatric providers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Methicillin-resistant Staphylococcus aureus disease in three communities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Three-year surveillance of community-acquired Staphylococcus aureus infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Community-associated meticillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Methicillin-resistant Staphylococcus aureus in community-acquired skin infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Waves of resistance: Staphylococcus aureus in the antibiotic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Community-adapted methicillin-resistant Staphylococcus aureus (MRSA): population dynamics of an expanding community reservoir of MRSA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Community-associated methicillin-resistant Staphylococcus aureus in outpatients, United States, 1999-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Genotypic and phenotypic relationships among methicillin-resistant Staphylococcus aureus from three multicentre bacteraemia studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Susceptibilities of healthcare- and community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Efficacy of linezolid against Panton-Valentine leukocidin (PVL)-positive meticillin-resistant Staphylococcus aureus (MRSA) in a mouse model of haematogenous pulmonary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

The importance of bactericidal drugs: future directions in infectious disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Daptomycin: a review 4 years after first approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Influences of Linezolid, Penicillin, and Clindamycin, Alone and in Combination, on Streptococcal Pyrogenic Exotoxin A Release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Failure of Clindamycin Treatment of Methicillin-Resistant Staphylococcus aureus Expressing Inducible Clindamycin Resistance In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Chemical biology of tetracycline antibioticsThis paper is one of a selection of papers published in this Special Issue, entitled CSBMCB — Systems and Chemical Biology, and has undergone the Journal's usual peer review process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Minocycline--an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Tigecycline: first of a new class of antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Efficacy of trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus: a report from Tunisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Treatment of community-acquired methicillin-resistant Staphylococcus aureus in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Methicillin-sensitive and methicillin-resistant Staphylococcus aureus: management principles and selection of antibiotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

An antidote for Staphylococcus aureus pneumonia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Global analysis of community-associated methicillin-resistant Staphylococcus aureus exoproteins reveals molecules produced in vitro and during infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

New antimicrobial agents as therapy for resistant gram-positive cocci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Ceftaroline for complicated skin and skin-structure infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511614

10.1517/14656566.2010.511614

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference